Release Date: 11/08/16 10:03 Summary: Letter from Managing Director-ONT.AX Price Sensitive: No Download Document 824.64KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%